Widely used:Recently Viewed
Clear All₹25.35
₹-0.38
(-1.48%)
As on 13-Jun-2025IST
Today’s Range
52 Week Range
Liquidity
Market cap
₹109 Cr
Revenue (TTM)
₹45 Cr
Net Profit (TTM)
₹-17 Cr
ROE
0 %
ROCE
-25.6 %
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
-11.7
Div. Yield
0 %
Debt to Equity
-3
Book Value
₹-5.3
EPS
₹-3.9
Face value
10
Shares outstanding
43,180,000
CFO
₹-45.36 Cr
EBITDA
₹-45.38 Cr
Net Profit
₹-55.52 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bharat Immuno
| 6.8 | 14.1 | 17.4 | -12.9 | -3.0 | 14.3 | 0.5 |
|
BSE Healthcare
| -2.6 | 5.8 | 11.7 | 19.7 | 25.9 | 22.2 | 11.0 |
|
BSE Small Cap
| -2.6 | 9.6 | 21.0 | 6.2 | 27.3 | 35.1 | 17.6 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Bharat Immuno
| -32.2 | -11.4 | -31.7 | 12.0 | 598.8 | -38.5 | -65.8 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bharat Immuno
|
25.4 | 109.5 | 44.6 | -16.6 | -- | 0 | -- | -- |
| 279.6 | 4,381.3 | 2,711.5 | 3.2 | 6.5 | 0.5 | -- | 0.8 | |
| 47.2 | 14.4 | 0.8 | 0.4 | 50.5 | 9 | 40.6 | 3.7 | |
| 115.5 | 412.8 | 138.5 | 7.9 | 8.1 | 7.9 | 51.5 | 4.0 | |
| 259.3 | 11,743.7 | 2,622.8 | 382.6 | 17.0 | 16 | 30.9 | 4.8 | |
| 31.0 | 930.9 | 1,006.4 | 46.5 | 8.0 | 11 | 20 | 2.1 | |
| 5,056.0 | 11,671.2 | 667.6 | 168.3 | 37.0 | 82.8 | 69.3 | 36.2 | |
| 9.0 | 132.4 | 0.0 | 37.5 | -- | -- | 3.5 | 6.4 | |
| 38.0 | 69.9 | 46.7 | 7.3 | 24.6 | 10.6 | 9.6 | 1.0 |
No Review & Analysis are available.
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, ready to use therapeutic... food, low calorie sweetener tablets, etc. The company was founded in 1989 and is based in Bulandshahr, India. Read more
Incorporated
1989
Chairman
Sudhanshu Vrati
Managing Director
Dhananjay Kumar Tiwary
Group
PSU
Headquarters
Bulandshahar, Uttar Pradesh
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Bharat Immunologicals & Biologicals Corporation Ltd stood at ₹ 189 Cr as on 31-Mar-23
The share price of Bharat Immunologicals & Biologicals Corporation Ltd is ₹25.35 (BSE) as of 13-Jun-2025 IST. Bharat Immunologicals & Biologicals Corporation Ltd has given a return of -3.03% in the last 3 years.
Bharat Immunologicals & Biologicals Corporation Ltd has a market capitalisation of ₹ 109 Cr as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Bharat Immunologicals & Biologicals Corporation Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bharat Immunologicals & Biologicals Corporation Ltd and enter the required number of quantities and click on buy to purchase the shares of Bharat Immunologicals & Biologicals Corporation Ltd.
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, ready to use therapeutic food, low calorie sweetener tablets, etc. The company was founded in 1989 and is based in Bulandshahr, India.
The promoter of Bharat Immunologicals & Biologicals Corporation Ltd is PRESIDENT OF INDIA. PRESIDENT OF INDIA owns 59.25 per cent of the total equity. The chairman of the company is Sudhanshu Vrati , and the managing director is Dhananjay Kumar Tiwary..
There is no promoter pledging in Bharat Immunologicals & Biologicals Corporation Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,381
|
|
|
413
|
|
|
132
|
|
|
70
|
|
|
14
|
|
|
11,744
|
|
|
11,671
|
|
|
4,381
|
|
|
931
|
| Bharat Immunologicals & Biologicals Corporation Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
0
|
|
Operating margin(%)
|
-36.47
|
|
Net Margin(%)
|
-36.43
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Bharat Immunologicals & Biologicals Corporation Ltd was ₹-17 Cr.
